Non-small cell lung cancer (nsclc) Trials in Boston, United States
Conditions / Non-small cell lung cancer (nsclc) / Boston, United States
Non-small cell lung cancer (nsclc) has been the subject of sustained clinical investigation across multiple research sites.
23 total trials for this combination
Showing top 10 of 23 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07291037 | Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations | RECRUITING | — |
| NCT07227168 | A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer | RECRUITING | PHASE1 |
| NCT06026410 | KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors | RECRUITING | — |
| NCT06162221 | Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC | RECRUITING | PHASE1/PHASE2 |
| NCT07361497 | A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201) | RECRUITING | — |
| NCT05176483 | Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors | RECRUITING | PHASE1 |
| NCT05462717 | Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors | ACTIVE_NOT_RECRUITING | PHASE1 |
| NCT02588261 | A Study of ASP8273 vs. Erlotinib or Gefitinib in First-line Treatment of Patients With Stage IIIB/IV Non-small Cell Lung Cancer Tumors With EGFR Activating Mutations | TERMINATED | PHASE3 |
| NCT06128551 | Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors | RECRUITING | — |
| NCT02988817 | Enapotamab Vedotin (HuMax-AXL-ADC) Safety Study in Patients With Solid Tumors | COMPLETED | PHASE1/PHASE2 |